The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…


Supreme Court urged to weigh in on six-month biosimilar delays

Top of 2017's pharma heap? Pfizer, Novartis, Roche—and 7 drugs headed for biosim attack

With $496M CNS sale, Novartis joins the herd of pharmas casting off tired meds